International AIDS Vaccine Initiative Patent applications |
Patent application number | Title | Published |
20140322269 | ENGINEERED OUTER DOMAIN (EOD) OF HIV GP120 AND MUTANTS THEREOF - The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings. | 10-30-2014 |
20140212458 | NOVEL HIV-1 ENVELOPE GLYCOPROTEIN - The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron micrsocopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention. | 07-31-2014 |
20140205612 | HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES - The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided. | 07-24-2014 |
20130266989 | METHODS TO IMPROVE VECTOR EXPRESSION AND GENETIC STABILITY - The present invention relates to methods of developing gene inserts that are more compatible with the host vectors by modifying a protein sequence to lessen potential interference with vector propagation while ensuring that the protein is expressed and processed efficiently and maintains desired structural features, and designing a gene with a nucleotide sequence that resembles the base composition of the host vector genome. | 10-10-2013 |
20130266611 | RECOMBINANT VIRAL VECTORS - The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention. | 10-10-2013 |
20130251726 | NOVEL HIV -1 BROADLY NEUTRALIZING ANTIBODIES - The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided. | 09-26-2013 |
20130189754 | IMMUNOSELECTION OF RECOMBINANT VESICULAR STOMATITIS VIRUS EXPRESSING HIV-1 PROTEINS BY BROADLY NEUTRALIZING ANTIBODIES - The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention. | 07-25-2013 |
20130129778 | VIRAL PARTICLES DERIVED FROM AN ENVELOPED VIRUS - The invention relates to generating a vaccine based on immunogens from viral particles that initially have replication competency but are then inactivated by chemical, biophysical or other methods. The components of this vaccine may be a non-HIV enveloped virus that contains and expresses a gene related to the HIV Envelope gene such that the Envelope protein is expressed on the surface of viral particles. These viral particles may be further treated to reduce their replication competency. The vaccine further may contain components to improve its immunogenicity, tolerability, stability and ease of manufacture. | 05-23-2013 |
20130095556 | NOVEL VESICULAR STOMATITIS VIRUS AND VIRUS RESCUE SYSTEM - The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines as well as the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention. | 04-18-2013 |